$114.10
0.61% today
Nasdaq, Feb 05, 04:17 pm CET
ISIN
US09627Y1091
Symbol
BPMC
Sector
Industry

Blueprint Medicines Corp. Stock price

$113.40
+23.86 26.65% 1M
+20.43 21.97% 6M
+26.18 30.02% YTD
+36.74 47.93% 1Y
+35.00 44.64% 3Y
+49.46 77.35% 5Y
+94.53 500.95% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+1.90 1.70%
ISIN
US09627Y1091
Symbol
BPMC
Sector
Industry

Key metrics

Market capitalization $7.20b
Enterprise Value $7.20b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 16.58
P/S ratio (TTM) P/S ratio 16.58
P/B ratio (TTM) P/B ratio 22.98
Revenue growth (TTM) Revenue growth 100.93%
Revenue (TTM) Revenue $434.41m
EBIT (operating result TTM) EBIT $-275.95m
Free Cash Flow (TTM) Free Cash Flow $-250.52m
Cash position $734.17m
EPS (TTM) EPS $-2.11
P/E forward negative
P/S forward 14.16
EV/Sales forward 14.16
Short interest 9.12%
Show more

Is Blueprint Medicines Corp. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Blueprint Medicines Corp. Stock Analysis

Unlock Scores for Free

Analyst Opinions

21 Analysts have issued a Blueprint Medicines Corp. forecast:

15x Buy
71%
5x Hold
24%
1x Sell
5%

Analyst Opinions

21 Analysts have issued a Blueprint Medicines Corp. forecast:

Buy
71%
Hold
24%
Sell
5%

Financial data from Blueprint Medicines Corp.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
434 434
101% 101%
100%
- Direct Costs 27 27
41% 41%
6%
408 408
139% 139%
94%
- Selling and Administrative Expenses 328 328
35% 35%
76%
- Research and Development Expense 341 341
21% 21%
79%
-262 -262
48% 48%
-60%
- Depreciation and Amortization 14 14
47% 47%
3%
EBIT (Operating Income) EBIT -276 -276
48% 48%
-64%
Net Profit -128 -128
77% 77%
-29%

In millions USD.

Don't miss a Thing! We will send you all news about Blueprint Medicines Corp. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Blueprint Medicines Corp. Stock News

Neutral
PRNewsWire
about 3 hours ago
CAMBRIDGE, Mass. , Feb. 5, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m.
Neutral
PRNewsWire
24 days ago
-- Updating peak systemic mastocytosis franchise revenue opportunity to $4 billion, catalyzed by strong AYVAKIT® (avapritinib) launch and evolving SM prevalence estimates --  -- Expect to achieve $2 billion in AYVAKIT revenue by 2030 -- -- BLU-808 demonstrates wide therapeutic window with rapid, robust and sustained tryptase reductions exceeding 80% in Phase 1 healthy volunteer study -- -- Kate...
Neutral
PRNewsWire
about 2 months ago
CAMBRIDGE, Mass. , Dec. 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that Kate Haviland, Chief Executive Officer, will present a corporate overview and 2025 outlook at the 43rd Annual J.P.
More Blueprint Medicines Corp. News

Company Profile

Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

Head office United States
CEO Kathryn Haviland
Employees 655
Founded 2008
Website www.blueprintmedicines.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today